Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 2/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985142 | 0.87 | MCHR1 (0.37) | MCHR1HRH3PYGL | |
| SCHEMBL2991825 | 0.84 | MCHR1 (0.37) | MCHR1HRH3CCR5UBE2MDCUN1D1 | |
| SCHEMBL2988692 | 0.81 | MCHR1 (0.42) | MCHR1HRH3CCR5KCNH2 | |
| SCHEMBL2982702 | 0.80 | KDM4E (0.39) | PLA2G1BATG4B | |
| SCHEMBL2991824 | 0.72 | MCHR1 (0.36) | MCHR1HRH3CCR5 | |
| SCHEMBL5228399 | 0.70 | MCHR1 (0.35) | MCHR1HRH3CCR5 | |
| SCHEMBL2982698 | 0.69 | KDM4E (0.35) | PLA2G1BATG4B | |
| SCHEMBL2995119 | 0.69 | HRH3 (0.38) | MCHR1HRH3CCR5KCNH2 | |
| SCHEMBL2988690 | 0.69 | MCHR1 (0.41) | MCHR1HRH3CCR5KCNH2 | |
| SCHEMBL2989200 | 0.69 | POLB (0.42) | MCHR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ZC3HAV1, XDH, TPMT | MCHR1 2771/4885HRH3 1724/4885CCR5 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.